메뉴 건너뛰기




Volumn 20, Issue 121, 2011, Pages 175-182

Beyond corticosteroids: Future prospects in the management of inflammation in COPD

(18)  Roche, N a   Marthan, R b   Berger, P b   Chambellan, A c   Chanez, P d   Aguilaniu, B e   Brillet, P Y f   Burgel, P R a   Chaouat, A g   Devillier, P h   Escamilla, R i   Louis, R j   Mal, H k   Muir, J F l   Perez T m   Similowski, T a   Wallaert, B m   Aubier, M k  

e HYLAB   (France)

Author keywords

Chronic obstructive pulmonary disease; Inflammation; Mucus hypersecretion; Phosphodiesterase 4 inhibitors; Repair; Treatment

Indexed keywords

ACETYLCYSTEINE; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROSIGLITAZONE; SALMETEROL; THEOPHYLLINE;

EID: 80052606325     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00004211     Document Type: Review
Times cited : (36)

References (80)
  • 1
    • 33847172367 scopus 로고    scopus 로고
    • Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease
    • Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
    • (2007) N Engl J Med , vol.356 , pp. 775-789
    • Calverley, P.M.1    Anderson, J.A.2    Celli, B.3
  • 2
    • 48949103222 scopus 로고    scopus 로고
    • Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study
    • Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
    • (2008) Am J Respir Crit Care Med , vol.178 , pp. 332-338
    • Celli, B.R.1    Thomas, N.E.2    Anderson, J.A.3
  • 3
    • 53749102775 scopus 로고    scopus 로고
    • A 4-year trial of tiotropium in chronic obstructive pulmonary disease
    • Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
    • (2008) N Engl J Med , vol.359 , pp. 1543-1554
    • Tashkin, D.P.1    Celli, B.2    Senn, S.3
  • 4
    • 79953083992 scopus 로고    scopus 로고
    • BPCO et inflammation: Mise au point d'un group d'experts. Les mécanismes de l'inflammation et du remodelage
    • Aubier M, Marthan R, Berger P, et al. BPCO et inflammation: mise au point d'un group d'experts. Les mécanismes de l'inflammation et du remodelage [COPD and inflammation: statement from a French expert group: inflammation and remodelling mechanisms]. Rev Mal Respir 2010; 27: 1254-1266.
    • (2010) Rev Mal Respir , vol.27 , pp. 1254-1266
    • Aubier, M.1    Marthan, R.2    Berger, P.3
  • 5
    • 85017458214 scopus 로고    scopus 로고
    • BPCO et inflammation: Mise au point d'un group d'experts. Les phénotypes en lien avec l'inflammation
    • Pérez T, Mal H, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Les phénotypes en lien avec l'inflammation [COPD and inflammation: statement from a French expert group. Phenotypes related to inflammation]. Rev Mal Respir 2011; 28: 192-215.
    • (2011) Rev Mal Respir , vol.28 , pp. 192-215
    • Pérez, T.1    Mal, H.2    Aguilaniu, B.3
  • 6
    • 79959551393 scopus 로고    scopus 로고
    • BPCO et inflammation: Mise au point d'un group d'experts. Comment traiter l'inflammation?
    • Roche N, Devillier P, Aguilaniu B, et al. BPCO et inflammation: mise au point d'un group d'experts. Comment traiter l'inflammation? [COPD and inflammation: statement from a French expert group. How to treat inflammation?]. Rev Mal Respir 2011; 28: 427-442.
    • (2011) Rev Mal Respir , vol.28 , pp. 427-442
    • Roche, N.1    Devillier, P.2    Aguilaniu, B.3
  • 7
    • 0027410275 scopus 로고
    • Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis
    • Saetta M, Di Stefano A, Maestrelli P, et al. Activated T-lymphocytes and macrophages in bronchial mucosa of subjects with chronic bronchitis. Am Rev Respir Dis 1993; 147: 301-306.
    • (1993) Am Rev Respir Dis , vol.147 , pp. 301-306
    • Saetta, M.1    di Stefano, A.2    Maestrelli, P.3
  • 8
    • 2942720573 scopus 로고    scopus 로고
    • The nature of small-airway obstruction in chronic obstructive pulmonary disease
    • Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653.
    • (2004) N Engl J Med , vol.350 , pp. 2645-2653
    • Hogg, J.C.1    Chu, F.2    Utokaparch, S.3
  • 9
    • 66649127821 scopus 로고    scopus 로고
    • Immunologic aspects of chronic obstructive pulmonary disease
    • Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
    • (2009) N Engl J Med , vol.360 , pp. 2445-2454
    • Cosio, M.G.1    Saetta, M.2    Agusti, A.3
  • 10
    • 72549087224 scopus 로고    scopus 로고
    • Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease
    • Freeman CM, Martinez FJ, Han MK, et al. Lung dendritic cell expression of maturation molecules increases with worsening chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 1179-1188.
    • (2009) Am J Respir Crit Care Med , vol.180 , pp. 1179-1188
    • Freeman, C.M.1    Martinez, F.J.2    Han, M.K.3
  • 11
    • 69249128696 scopus 로고    scopus 로고
    • Lymphoid follicles in (very) severe COPD: Beneficial or harmful?
    • Brusselle GG, Demoor T, Bracke KR, et al. Lymphoid follicles in (very) severe COPD: beneficial or harmful? Eur Respir J 2009; 34: 219-230.
    • (2009) Eur Respir J , vol.34 , pp. 219-230
    • Brusselle, G.G.1    Demoor, T.2    Bracke, K.R.3
  • 13
    • 57349099228 scopus 로고    scopus 로고
    • Emerging Pharmacotherapies for COPD
    • Barnes PJ. Emerging Pharmacotherapies for COPD. Chest 2008; 134: 1278-1286.
    • (2008) Chest , vol.134 , pp. 1278-1286
    • Barnes, P.J.1
  • 14
    • 17644373481 scopus 로고    scopus 로고
    • Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease
    • MacNee W. Pulmonary and systemic oxidant/antioxidant imbalance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 50-60.
    • (2005) Proc Am Thorac Soc , vol.2 , pp. 50-60
    • Macnee, W.1
  • 15
    • 32644486046 scopus 로고    scopus 로고
    • Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease - a new take on an old hypothesis
    • Stevenson CS, Koch LG, Britton SL. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease - a new take on an old hypothesis. Pharmacol Ther 2006; 110: 71-82.
    • (2006) Pharmacol Ther , vol.110 , pp. 71-82
    • Stevenson, C.S.1    Koch, L.G.2    Britton, S.L.3
  • 16
    • 58249099942 scopus 로고    scopus 로고
    • COPD as a disease of accelerated lung aging
    • Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
    • (2009) Chest , vol.135 , pp. 173-180
    • Ito, K.1    Barnes, P.J.2
  • 17
    • 65849427529 scopus 로고    scopus 로고
    • Glucocorticoid resistance in inflammatory diseases
    • Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905-17.
    • (2009) Lancet , vol.373 , pp. 1905-1917
    • Barnes, P.J.1    Adcock, I.M.2
  • 18
    • 27144526596 scopus 로고    scopus 로고
    • Airway and systemic inflammation and decline in lung function in patients with COPD
    • Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128: 1995-2004.
    • (2005) Chest , vol.128 , pp. 1995-2004
    • Donaldson, G.C.1    Seemungal, T.A.2    Patel, I.S.3
  • 19
    • 77956689733 scopus 로고    scopus 로고
    • Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease
    • Hurst JR, Vestbo J, Anzueto A, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
    • (2010) N Engl J Med , vol.363 , pp. 1128-1138
    • Hurst, J.R.1    Vestbo, J.2    Anzueto, A.3
  • 20
    • 0030061718 scopus 로고    scopus 로고
    • Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa
    • Di Stefano A, Turato G, Maestrelli P, et al. Airflow limitation in chronic bronchitis is associated with T-lymphocyte and macrophage infiltration of the bronchial mucosa. Am J Respir Crit Care Med 1996; 153: 629-632.
    • (1996) Am J Respir Crit Care Med , vol.153 , pp. 629-632
    • di Stefano, A.1    Turato, G.2    Maestrelli, P.3
  • 21
    • 0030900606 scopus 로고    scopus 로고
    • Inflammation in bronchial biopsies of subjects with chronic bronchitis: Inverse relationship of CD8 T lymphocytes with FEV1
    • O'Shaughnessy TC, Ansari TW, Barnes NC, et al. Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8 T lymphocytes with FEV1. Am J Respir Crit Care Med 1997; 155: 852-857.
    • (1997) Am J Respir Crit Care Med , vol.155 , pp. 852-857
    • O'Shaughnessy, T.C.1    Ansari, T.W.2    Barnes, N.C.3
  • 22
    • 0035421665 scopus 로고    scopus 로고
    • Amplification of inflammation in emphysema and its association with latent adenoviral infection
    • Retamales I, Elliott WM, Meshi B, et al. Amplification of inflammation in emphysema and its association with latent adenoviral infection. Am J Respir Crit Care Med 2001; 164: 469-473.
    • (2001) Am J Respir Crit Care Med , vol.164 , pp. 469-473
    • Retamales, I.1    Elliott, W.M.2    Meshi, B.3
  • 23
    • 0033825960 scopus 로고    scopus 로고
    • Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function
    • Nakano Y, Muro S, Sakai H, et al. Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am J Respir Crit Care Med 2000; 162: 1102-1108.
    • (2000) Am J Respir Crit Care Med , vol.162 , pp. 1102-1108
    • Nakano, Y.1    Muro, S.2    Sakai, H.3
  • 24
    • 6344267160 scopus 로고    scopus 로고
    • Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD
    • O'Donnell RA, Peebles C, Ward JA, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004; 59: 837-842.
    • (2004) Thorax , vol.59 , pp. 837-842
    • O'Donnell, R.A.1    Peebles, C.2    Ward, J.A.3
  • 25
    • 0036644755 scopus 로고    scopus 로고
    • Airway inflammation in severe chronic obstructive pulmonary disease: Relationship with lung function and radiologic emphysema
    • Turato G, Zuin R, Miniati M, et al. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Am J Respir Crit Care Med 2002; 166: 105-110.
    • (2002) Am J Respir Crit Care Med , vol.166 , pp. 105-110
    • Turato, G.1    Zuin, R.2    Miniati, M.3
  • 26
    • 0036727140 scopus 로고    scopus 로고
    • Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations
    • Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
    • (2002) Thorax , vol.57 , pp. 759-764
    • Patel, I.S.1    Seemungal, T.A.2    Wilks, M.3
  • 27
    • 0034018102 scopus 로고    scopus 로고
    • Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations
    • Bhowmik A, Seemungal TAR, Sapsford RJ, et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax 2000; 55: 114-120.
    • (2000) Thorax , vol.55 , pp. 114-120
    • Bhowmik, A.1    Seemungal, T.A.R.2    Sapsford, R.J.3
  • 28
    • 0035509117 scopus 로고    scopus 로고
    • Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease
    • Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618-1623.
    • (2001) Am J Respir Crit Care Med , vol.164 , pp. 1618-1623
    • Seemungal, T.1    Harper-Owen, R.2    Bhowmik, A.3
  • 29
    • 58249088128 scopus 로고    scopus 로고
    • Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease
    • Baghai-Ravary R, Quint JK, Goldring JJ, et al. Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med 2009; 103: 216-223.
    • (2009) Respir Med , vol.103 , pp. 216-223
    • Baghai-Ravary, R.1    Quint, J.K.2    Goldring, J.J.3
  • 30
    • 12244264853 scopus 로고    scopus 로고
    • Systemic effects of chronic obstructive pulmonary disease
    • Agustý́ AG, Noguera A, Sauleda J, et al. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-360.
    • (2003) Eur Respir J , vol.21 , pp. 347-360
    • Agustý́, A.G.1    Noguera, A.2    Sauleda, J.3
  • 31
    • 33644620786 scopus 로고    scopus 로고
    • Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
    • Growcott EJ, Spink KG, Ren X, et al. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells. Respir Res 2006; 7: 9.
    • (2006) Respir Res , vol.7 , pp. 9
    • Growcott, E.J.1    Spink, K.G.2    Ren, X.3
  • 32
    • 67649873075 scopus 로고    scopus 로고
    • Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotalineinduced pulmonary hypertension in rats
    • Izikki M, Raffestin B, Klar J, et al. Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotalineinduced pulmonary hypertension in rats. J Pharmacol Exp Ther 2009; 330: 54-62.
    • (2009) J Pharmacol Exp Ther , vol.330 , pp. 54-62
    • Izikki, M.1    Raffestin, B.2    Klar, J.3
  • 33
    • 0030976501 scopus 로고    scopus 로고
    • Corticosteroid reversibility in COPD is related to features of asthma
    • Chanez P, Vignola AM, O'Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997; 155: 1529-1534.
    • (1997) Am J Respir Crit Care Med , vol.155 , pp. 1529-1534
    • Chanez, P.1    Vignola, A.M.2    O'Shaugnessy, T.3
  • 34
    • 0031045482 scopus 로고    scopus 로고
    • Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
    • Keatings V, Jatakanon A, Worsdell Y, et al. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 1997; 155: 548.
    • (1997) Am J Respir Crit Care Med , vol.155 , pp. 548
    • Keatings, V.1    Jatakanon, A.2    Worsdell, Y.3
  • 35
    • 0031841422 scopus 로고    scopus 로고
    • Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease
    • Confalonieri M, Mainardi E, Della Porta R, et al. Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 583-585.
    • (1998) Thorax , vol.53 , pp. 583-585
    • Confalonieri, M.1    Mainardi, E.2    della Porta, R.3
  • 36
    • 33645304010 scopus 로고    scopus 로고
    • Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease
    • Barnes NC, Qiu YS, Pavord ID, et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 2006; 173: 736-743.
    • (2006) Am J Respir Crit Care Med , vol.173 , pp. 736-743
    • Barnes, N.C.1    Qiu, Y.S.2    Pavord, I.D.3
  • 37
    • 0036153433 scopus 로고    scopus 로고
    • Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids
    • Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
    • (2002) Eur Respir J , vol.19 , pp. 182-191
    • Barnes, P.J.1
  • 38
    • 0037246566 scopus 로고    scopus 로고
    • Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
    • Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
    • (2003) Eur Respir J , vol.21 , pp. 74-81
    • Szafranski, W.1    Cukier, A.2    Ramirez, A.3
  • 39
    • 0345188819 scopus 로고    scopus 로고
    • Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease
    • Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953.
    • (1999) N Engl J Med , vol.340 , pp. 1948-1953
    • Pauwels, R.A.1    Lofdahl, C.G.2    Laitinen, L.A.3
  • 40
    • 0034643610 scopus 로고    scopus 로고
    • Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial
    • Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
    • (2000) BMJ , vol.320 , pp. 1297-1303
    • Burge, P.S.1    Calverley, P.M.2    Jones, P.W.3
  • 41
    • 0033614639 scopus 로고    scopus 로고
    • Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
    • Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823.
    • (1999) Lancet , vol.353 , pp. 1819-1823
    • Vestbo, J.1    Sorensen, T.2    Lange, P.3
  • 42
    • 77956344161 scopus 로고    scopus 로고
    • Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD
    • Worth H, Förster K, Eriksson G, et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-1459.
    • (2010) Respir Med , vol.104 , pp. 1450-1459
    • Worth, H.1    Förster, K.2    Eriksson, G.3
  • 43
    • 47049130249 scopus 로고    scopus 로고
    • Methodological issues in therapeutic trials of COPD
    • Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008; 31: 927-933.
    • (2008) Eur Respir J , vol.31 , pp. 927-933
    • Suissa, S.1    Ernst, P.2    Vandemheen, K.L.3
  • 44
    • 78649735324 scopus 로고    scopus 로고
    • Airway mucus function and dysfunction
    • Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-2247.
    • (2010) N Engl J Med , vol.363 , pp. 2233-2247
    • Fahy, J.V.1    Dickey, B.F.2
  • 45
    • 84856097024 scopus 로고    scopus 로고
    • Mucolytics and other therapeutic agents targeting mucociliary clearance
    • ed. Paris, Elsevier Masson SAS, 6-000-P-010
    • Chapron-Fouché J, Burgel PR. Mucolytics and other therapeutic agents targeting mucociliary clearance. In: EMC Pneumologie, ed. Paris, Elsevier Masson SAS, 2009; 6-000-P-010.
    • (2009) EMC Pneumologie
    • Chapron-Fouché, J.1    Burgel, P.R.2
  • 46
    • 77950937105 scopus 로고    scopus 로고
    • Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
    • Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; 2: CD001287.
    • (2010) Cochrane Database Syst Rev , vol.2
    • Poole, P.J.1    Black, P.N.2
  • 47
    • 20944433417 scopus 로고    scopus 로고
    • Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial
    • Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
    • (2005) Lancet , vol.365 , pp. 1552-1560
    • Decramer, M.1    Rutten-Van, M.M.2    Dekhuijzen, P.N.3
  • 48
    • 34249652351 scopus 로고    scopus 로고
    • Antielastin autoimmunity in tobacco smoking-induced emphysema
    • Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007; 13: 567-569.
    • (2007) Nat Med , vol.13 , pp. 567-569
    • Lee, S.H.1    Goswami, S.2    Grudo, A.3
  • 49
    • 67349212939 scopus 로고    scopus 로고
    • Matrix metalloproteinase 12 silencing: A therapeutic approach to treat pathological lung tissue remodeling?
    • Garbacki N, Di Valentin E, Piette J, et al. Matrix metalloproteinase 12 silencing: a therapeutic approach to treat pathological lung tissue remodeling? Pulm Pharmacol Ther 2009; 22: 267-278.
    • (2009) Pulm Pharmacol Ther , vol.22 , pp. 267-278
    • Garbacki, N.1    di Valentin, E.2    Piette, J.3
  • 50
    • 74049134939 scopus 로고    scopus 로고
    • MMP12, lung function, and COPD in high-risk populations
    • Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361: 2599-2608.
    • (2009) N Engl J Med , vol.361 , pp. 2599-2608
    • Hunninghake, G.M.1    Cho, M.H.2    Tesfaigzi, Y.3
  • 51
    • 59849113942 scopus 로고    scopus 로고
    • Attacking the multitiered proteolytic pathology of COPD: New insights from basic and translational studies
    • Djekic UV, Gaggar A, Weathington NM. Attacking the multitiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009; 121: 132-146.
    • (2009) Pharmacol Ther , vol.121 , pp. 132-146
    • Djekic, U.V.1    Gaggar, A.2    Weathington, N.M.3
  • 52
    • 56749157688 scopus 로고    scopus 로고
    • Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations
    • Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
    • (2008) Am J Respir Crit Care Med , vol.178 , pp. 1139-1147
    • Seemungal, T.A.1    Wilkinson, T.M.2    Hurst, J.R.3
  • 53
    • 51649104671 scopus 로고    scopus 로고
    • Advances in neutrophil biology: Clinical implications
    • Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008; 134: 606-612.
    • (2008) Chest , vol.134 , pp. 606-612
    • Cowburn, A.S.1    Condliffe, A.M.2    Farahi, N.3
  • 54
    • 53149136171 scopus 로고    scopus 로고
    • Chemotaxis, chemokine receptors and human disease
    • Jin T, Xu X, Hereld D. Chemotaxis, chemokine receptors and human disease. Cytokine 2008; 44: 1-8.
    • (2008) Cytokine , vol.44 , pp. 1-8
    • Jin, T.1    Xu, X.2    Hereld, D.3
  • 56
    • 57749100072 scopus 로고    scopus 로고
    • CXCR2 antagonists for the treatment of pulmonary disease
    • Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009; 121: 55-68.
    • (2009) Pharmacol Ther , vol.121 , pp. 55-68
    • Chapman, R.W.1    Phillips, J.E.2    Hipkin, R.W.3
  • 57
    • 33748580720 scopus 로고    scopus 로고
    • Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease
    • Donnelly LE, Barnes PJ. Chemokine receptors as therapeutic targets in chronic obstructive pulmonary disease. Trends Pharmacol Sci 2006; 27: 546-553.
    • (2006) Trends Pharmacol Sci , vol.27 , pp. 546-553
    • Donnelly, L.E.1    Barnes, P.J.2
  • 58
    • 33644755474 scopus 로고    scopus 로고
    • Agents against cytokine synthesis or receptors
    • Yamagata T, Ichinose M. Agents against cytokine synthesis or receptors. Eur J Pharmacol 2006; 533: 289-301.
    • (2006) Eur J Pharmacol , vol.533 , pp. 289-301
    • Yamagata, T.1    Ichinose, M.2
  • 59
    • 34249045684 scopus 로고    scopus 로고
    • Emerging trends in the therapy of COPD: Novel anti-inflammatory agents in clinical development
    • Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov Today 2007; 12: 479-486.
    • (2007) Drug Discov Today , vol.12 , pp. 479-486
    • Fitzgerald, M.F.1    Fox, J.C.2
  • 60
    • 4544379912 scopus 로고    scopus 로고
    • Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages
    • Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004; 200: 689-695.
    • (2004) J Exp Med , vol.200 , pp. 689-695
    • Cosio, B.G.1    Tsaprouni, L.2    Ito, K.3
  • 61
    • 77953310216 scopus 로고    scopus 로고
    • Treatment effects of lowdose theophylline combined with an inhaled corticosteroid in COPD
    • Ford PA, Durham AL, Russell REK, et al. Treatment effects of lowdose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010; 137: 1338-1344.
    • (2010) Chest , vol.137 , pp. 1338-1344
    • Ford, P.A.1    Durham, A.L.2    Russell, R.E.K.3
  • 62
    • 36749063803 scopus 로고    scopus 로고
    • Reduction in sputum neutrophil and eosinophil by the PDE4 inhibitor roflumilast in patients with COPD
    • Grootendorst DC, Gauw SA, Verhoosel RM, et al. Reduction in sputum neutrophil and eosinophil by the PDE4 inhibitor roflumilast in patients with COPD. Thorax 2007; 62: 1081-1087.
    • (2007) Thorax , vol.62 , pp. 1081-1087
    • Grootendorst, D.C.1    Gauw, S.A.2    Verhoosel, R.M.3
  • 63
    • 0142012148 scopus 로고    scopus 로고
    • Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease
    • Gamble E, Grootendorst DC, Brightling CE, et al. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 168: 976-982.
    • (2003) Am J Respir Crit Care Med , vol.168 , pp. 976-982
    • Gamble, E.1    Grootendorst, D.C.2    Brightling, C.E.3
  • 64
    • 69149103642 scopus 로고    scopus 로고
    • Roflumilast in symptomatic chronic obstructive pulmonary disease: Two randomized clinical trials
    • Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomized clinical trials. Lancet 2009; 374: 685-694.
    • (2009) Lancet , vol.374 , pp. 685-694
    • Calverley, P.M.1    Rabe, K.F.2    Goehring, U.M.3
  • 65
    • 69149098943 scopus 로고    scopus 로고
    • Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: Two randomised clinical trials
    • Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
    • (2009) Lancet , vol.374 , pp. 695-703
    • Fabbri, L.M.1    Calverley, P.M.2    Izquierdo-Alonso, J.L.3
  • 66
    • 44649152300 scopus 로고    scopus 로고
    • Macrolides as immunomodulatory medications for the therapy of chronic lung diseases
    • López-Boado YS, Rubin BK. Macrolides as immunomodulatory medications for the therapy of chronic lung diseases. Curr Opin Pharmacol 2008; 8: 286-291.
    • (2008) Curr Opin Pharmacol , vol.8 , pp. 286-291
    • López-Boado, Y.S.1    Rubin, B.K.2
  • 67
    • 56749157688 scopus 로고    scopus 로고
    • Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations
    • Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
    • (2008) Am J Respir Crit Care Med , vol.178 , pp. 1139-1147
    • Seemungal, T.A.1    Wilkinson, T.M.2    Hurst, J.R.3
  • 68
    • 80052590900 scopus 로고    scopus 로고
    • Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations
    • Albert RK, Bailey WC, Casaburi R, et al. Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2011; 183: A6416.
    • (2011) Am J Respir Crit Care Med , vol.183
    • Albert, R.K.1    Bailey, W.C.2    Casaburi, R.3
  • 69
    • 68149180708 scopus 로고    scopus 로고
    • Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: A review of the evidence
    • Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J 2009; 85: 414-421.
    • (2009) Postgrad Med J , vol.85 , pp. 414-421
    • Young, R.P.1    Hopkins, R.2    Eaton, T.E.3
  • 70
    • 68349104141 scopus 로고    scopus 로고
    • Associations between statins and COPD: A systematic review
    • Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009; 9: 32.
    • (2009) BMC Pulm Med , vol.9 , pp. 32
    • Dobler, C.C.1    Wong, K.K.2    Marks, G.B.3
  • 71
    • 69249112121 scopus 로고    scopus 로고
    • Statins in COPD. A systematic review
    • Janda S, Park K, Fitzgerald M, et al. Statins in COPD. A systematic review. Chest 2009; 136: 734-743.
    • (2009) Chest , vol.136 , pp. 734-743
    • Janda, S.1    Park, K.2    Fitzgerald, M.3
  • 72
    • 49349115994 scopus 로고    scopus 로고
    • Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: Evidence form a retrospective cohort study
    • Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence form a retrospective cohort study. Int J Clin Pract 2008; 62: 1373-1378.
    • (2008) Int J Clin Pract , vol.62 , pp. 1373-1378
    • Blamoun, A.I.1    Batty, G.N.2    Debari, V.A.3
  • 73
    • 33846931592 scopus 로고    scopus 로고
    • Statin use is associated with reduced mortality of COPD
    • Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality of COPD. Eur Respir J 2007; 29: 279-283.
    • (2007) Eur Respir J , vol.29 , pp. 279-283
    • Soyseth, V.1    Brekke, P.H.2    Smith, P.3
  • 74
    • 70249144367 scopus 로고    scopus 로고
    • Impact of statins and ACE inhibitors on mortality after COPD exacerbations
    • Mortensen EM, Copeland LA, Pugh MJV, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45.
    • (2009) Respir Res , vol.10 , pp. 45
    • Mortensen, E.M.1    Copeland, L.A.2    Pugh, M.J.V.3
  • 75
    • 37549021118 scopus 로고    scopus 로고
    • The use of statins and lung function in current and former smokers
    • Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
    • (2007) Chest , vol.132 , pp. 1764-1771
    • Keddissi, J.I.1    Younis, W.G.2    Chbeir, E.A.3
  • 76
    • 35348972883 scopus 로고    scopus 로고
    • Statin use reduces decline in lung function: VA Normative Aging Study
    • Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747.
    • (2007) Am J Respir Crit Care Med , vol.176 , pp. 742-747
    • Alexeeff, S.E.1    Litonjua, A.A.2    Sparrow, D.3
  • 77
    • 38849125493 scopus 로고    scopus 로고
    • Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin
    • Lee TM, Lin MS, Chang NC. Usefulnes of C-reactive protein and interleukin-6 as predictors of outcomes in patients with chronic obstructive pulmonary disease receiving pravastatin. Am J Cardiol 2008; 101: 530-535.
    • (2008) Am J Cardiol , vol.101 , pp. 530-535
    • Lee, T.M.1    Lin, M.S.2    Chang, N.C.3
  • 78
    • 33748701308 scopus 로고    scopus 로고
    • Regulation of inflammation by PPARs: A future approach to treat lung inflammatory diseases?
    • Becker J, Delayre-Orthez C, Frossard N, et al. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20: 429-447.
    • (2006) Fundam Clin Pharmacol , vol.20 , pp. 429-447
    • Becker, J.1    Delayre-Orthez, C.2    Frossard, N.3
  • 79
    • 33845468172 scopus 로고    scopus 로고
    • Peroxisome proliferatoractivated receptors-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease
    • Spears M, McSharry C, Thomson NC. Peroxisome proliferatoractivated receptors-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 2006; 36: 1494-1504.
    • (2006) Clin Exp Allergy , vol.36 , pp. 1494-1504
    • Spears, M.1    McSharry, C.2    Thomson, N.C.3
  • 80
    • 3543104442 scopus 로고    scopus 로고
    • PPAR-gamma agonists as therapy for diseases involving airway neutrophilia
    • Birrell MA, Patel HJ, McCluskie K, et al. PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.
    • (2004) Eur Respir J , vol.24 , pp. 18-23
    • Birrell, M.A.1    Patel, H.J.2    McCluskie, K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.